Showing 1-10 of about 20 articles.
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade The Epidermolysis bullosa clinical...
Amryt Pharma Plc
AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103 DUBLIN, Ireland, and Boston MA, September 15 2020, Amryt (Nasdaq: AMYT,...
EB Research Partnership
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis...
EB Research Partnership
HOUSTON, April 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), is...
EB Research Partnership
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing the devastating and...
EB Research Partnership
BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), is...
EB Research Partnership
NEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- EB Research Partnership, the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB),...
EB Research Partnership
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), based in New York, and Australian-based EB Research Foundation, today announced a global collaboration to accelerate their...
ProQR Therapeutics N.V.
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a...
ProQR Therapeutics N.V.
The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) --...
Showing 1-10 of about 20 articles.
